Policy | August 27, 2025
GST rejig may impact competitiveness of medical devices: AiMeD
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
Delegates also visited Emami’s WHO-GMP-certified manufacturing plant and Zandu Foundation for Healthcare farms for hands-on exposure to quality practices,
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
Guidelines aim to establish state-regulated veterinary blood banks
Terufusion Advanced Infusion Systems combine a smart syringe pump, smart infusion pump, and pump monitoring system software for precise and efficient drug administration
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
The company is bringing precision therapies for gynaecological cancers
Subscribe To Our Newsletter & Stay Updated
